Real-World Effectiveness of Bimekizumab in Predominantly Difficult-to-Treat Patients with Psoriatic Arthritis Followed in a Combined Dermatology–Rheumatology Clinic: A 24-Week Multicenter Study

Abstract Introduction Bimekizumab (BKZ), a monoclonal antibody targeting interleukin (IL)-17A and IL-17F, has shown high efficacy in clinical trials. However, real-world data on its use in psoriatic arthritis (PsA) are limited. This study aimed to evaluate the effectiveness and safety of BKZ over 24...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Alen Zabotti, Nicola Cabas, Maria De Martino, Luca Idolazzi, Andrea Guiotto, Francesco Bellinato, Ivan Giovannini, Beatrice Gabrielli, Paolo Gisondi, Enzo Errichetti, Maurizio Rossini, Giuseppe Stinco, Luca Quartuccio
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Adis, Springer Healthcare 2025-07-01
Schriftenreihe:	Rheumatology and Therapy
Schlagworte:	Psoriatic arthritis b/tsDMARDs Difficult-to-treat Real-world evidence
Online-Zugang:	https://doi.org/10.1007/s40744-025-00784-4
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!